Close

Roth Capital Comments on New SERM Lasofoxifene Phase 1 Data

June 23, 2014 11:28 AM EDT Send to a Friend
Roth Capital affirms Ligand Pharmaceuticals, Inc. (Nasdaq: LGND) at Buy with a price target of $92 following a positive update ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login